NYSE:IQV - Iqvia Stock Price, Forecast & News

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) issued its earnings results on Wednesday, October, 30th. The medical research company reported $1.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.57 by $0.03. The medical research company earned $2.77 billion during the quarter, compared to analysts' expectations of $2.76 billion. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The business's revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.42 EPS. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Iqvia.

Iqvia issued an update on its fourth quarter earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of $1.65-1.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.75. The company issued revenue guidance of $2.807-2.857 billion, compared to the consensus revenue estimate of $2.89 billion.

18 brokers have issued 1-year price targets for Iqvia's stock. Their forecasts range from $136.38 to $185.00. On average, they anticipate Iqvia's share price to reach $167.83 in the next year. This suggests a possible upside of 4.4% from the stock's current price. View Analyst Price Targets for Iqvia.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Media stories about IQV stock have trended positive on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Iqvia.

Iqvia saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 3,280,000 shares, a decline of 7.6% from the November 28th total of 3,550,000 shares. Based on an average trading volume of 1,360,000 shares, the short-interest ratio is presently 2.4 days. Currently, 1.9% of the shares of the company are sold short. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), Allergan (AGN), Alibaba Group (BABA), Athabasca Oil (ATH), Paypal (PYPL) and Accenture (ACN).

Iqvia's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Arvest Bank Trust Division (0.11%), Artemis Investment Management LLP (0.07%), Howard Capital Management (0.06%), DNB Asset Management AS (0.06%), McGuire Investment Group LLC (0.05%) and State of Alaska Department of Revenue (0.04%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, First Hawaiian Bank, State of Alaska Department of Revenue, Howard Capital Management, Arvest Bank Trust Division, Legacy Capital Partners Inc., Winslow Evans & Crocker Inc. and HWG Holdings LP. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

IQV stock was bought by a variety of institutional investors in the last quarter, including McGuire Investment Group LLC, DNB Asset Management AS, Three Peaks Capital Management LLC, IFM Investors Pty Ltd, FTB Advisors Inc., Appleton Partners Inc. MA, Raymond James Trust N.A. and IFP Advisors Inc. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $160.70.

Iqvia has a market capitalization of $31.18 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]